Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Microsulis: Firm will use $45 mil. round financing to hire 50 direct sales reps/physician educators to support full launch of Microwave Endometrial Ablation (MEA) system to treat menorrhagia. Approved last September, MEA has been slowly rolled out, awaiting funding for clinical specialists required under FDA clearance (1"The Gray Sheet" Oct. 20, 2003, In Brief). Microsulis currently is evaluating distributors for metropolitan areas. The funds also will go to support separate 510(k) applications for soft tissue ablation and peripheral vascular indications to be submitted by year-end. Existing investors contributed $20 mil. to the round, while the remaining $25 mil. came from venture capital...

Related Content

NuVasive IPO: Minimally Invasive Spine Firm Offers Up To $92 Mil. In Stock
Angiodynamics To Realize Independence From E-Z-Em Through IPO
Animas IPO: Insulin Pump Maker Offers Up To $69 Mil. In Stock
Microsulis launches MEA system



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts